

ATTENTION: BOX AFTER FINAL RESPONSE UNDER 37 C.F.R. § 1.116 EXPEDITED PROCEDURE REQUESTED EXAMINING GROUP 1600

PATENT

Attorney Docket No. 2481.1337-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:		.	RECEIVE-	
Mathias GEHRMANN et al.				
Serial	No.: 08/989,896	Group Art Unit: 1644		
Filed:	December 12, 1997	Examiner: D. Saunders	TECH CENTER 1600/2900	
For:	FUSION PROTEINS FOR PRODRUG ACTIVATION)))Attention: BOX AFTER FINAL		
Assistant Commissioner for Patents Washington, DC 20231				
Sir:				

AMENDMENT AFTER FINAL

In response to the Final Office Action of August 7, 2000, and pursuant to 37 C.F.R. § 1.116, Applicants propose that this application be amended as follows:

IN THE CLAIMS:

Please amend claims 1, 2, 3, 29, and 30 as follows:

1. (Thrice Amended) A compound comprising [an] at least one antigen binding region linked to at least one prodrug-activating enzyme, where the antigen binding [region] region(s) is composed of a single polypeptide chain, and where the [antigen binding region] compound has a bivalent or a multivalent structure.

LAW OFFICE S
FINNIGAN, HENDERSON,
FARABOW, GARRETT,
& DINNIER, L.L.P.
BOO I STREET, N. W.
WASHINGTON, DC 20005
202 408 4000

part page 2 mot